6-乙基-4-羟基喹啉-3-羧酸乙酯 | 85418-73-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-乙基-4-羟基喹啉-3-羧酸乙酯
• 英文名称: ethyl 6-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylate
• 英文别名: ethyl 6-ethyl-4-hydroxyquinoline-3-carboxylate
• CAS: 85418-73-1
• 化学式: C₁₄H₁₅NO₃
• mdl: MFCD07629412
• 分子量: 245.278
• InChiKey: ZFOFJXFVCJQXBL-UHFFFAOYSA-N

物化性质

• 沸点：
  364.2±37.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-乙基-4-羟基喹啉-3-羧酸乙酯 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 6-乙基-4-羟基喹啉-3-羧酸
  参考文献：
  名称：

  2- [ 18 F]氟乙基叠氮化物在施陶丁格连接中的用途–结合GABA A受体的4-喹诺酮的制备和表征

  摘要：

  标记试剂2- [ 18 F]氟乙基叠氮化物用于无痕Staudinger连接。该反应用于获得结合了6-苄基-4-氧代-1，4-二氢喹啉-3-羧酸（2- [ 18 F]氟乙基）酰胺的GABA A受体。制备的放射性示踪剂的无衰减校正放射化学产率为7％，放射化学纯度> 95％，比放射性为0.9 GBq /μmol。该化合物在正常大鼠中脑渗透率低。还已经制备了一系列对GABA A受体具有纳摩尔至亚纳摩尔亲和力的氟代烷基4-喹诺酮类似物。

  DOI：

  10.1016/j.bmcl.2010.05.106
• 作为产物：
  描述：

  4-乙基苯胺 以 二苯醚 为溶剂， 反应 3.0h， 生成 6-乙基-4-羟基喹啉-3-羧酸乙酯
  参考文献：
  名称：

  4-Quinolone Derivatives:  High-Affinity Ligands at the Benzodiazepine Site of Brain GABA_A Receptors. Synthesis, Pharmacology, and Pharmacophore Modeling

  摘要：

  The 3-ethoxycarbonyl-4-quinolone compound I has previously been identified via a database search as an interesting lead compound for ligand binding at the benzodiazepine site of GABA(A) receptors (Kahnberg et al. J. Mol. Graphics Modelling 2004, 23, 253-261). Pharmacophore-guided optimization of this lead compound yielded a number of high-affinity ligands for the benzodiazepine site including compounds 20 and 23-25 displaying sub-nanomolar affinities. A few of the compounds have been tested on the alpha(1)beta(2)gamma(2s) and alpha(3)beta(2)gamma(2s) GABA(A) receptor subtypes, and two of the compounds (5 and 19) display selectivity for alpha(1) versus alpha(3)-containing receptors by a factor of 22 and 27, respectively. This selectivity for alpha(1)beta(2)gamma(2s) is in the same range as that for the well-known alpha(1) subunit selective compound zolpidem.

  DOI：

  10.1021/jm058057p

文献信息

• [EN] AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE<br/>[FR] AGENTS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES ET INFLAMMATOIRES AYANT UNE STRUCTURE BASÉE SUR LA 4(1H)-QUINOLONE
  申请人：UCL BUSINESS PLC

  公开号：WO2015189560A1

  公开（公告）日：2015-12-17

  The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of a cardiovascular disease or of an inflammatory disease or condition:

  本发明提供了一种式I的化合物，其互变异构体，或其药用可接受的盐或N-氧化物，用于治疗或预防心血管疾病或炎症性疾病或症状。
• Conjugate Addition Routes to 2‐Alkyl‐2,3‐dihydroquinolin‐4(1 <i>H</i> )‐ones and 2‐Alkyl‐4‐hydroxy‐1,2‐dihydroquinoline‐3‐carboxylates
  作者：Alex Kingsbury、Steve Brough、Antonio Pedrina McCarthy、William Lewis、Simon Woodward

  DOI：10.1002/ejic.201901036

  日期：2020.3.27

  quinolin‐4(1H)‐ones to provide 2‐alkyl‐2,3‐dihydroquinolin‐4(1H)‐ones (14 examples, 54–99 % yield). Asymmetric versions require AlEt3 to Boc‐protected ethyl 6‐substituted 4(1H)‐quinolone‐3‐carboxylates (6‐R group = all halogens, n/i/t‐alkyls, CF3) and provide 61–91 % yield, 30–86 % ee; any halogen, Me, or CF3 provide the highest stereoselectivities (76–86 % ee). Additions of AlMe3 or Al(nC8H17)3 provide ≈ 45 and

  在CuBr · SMe2 / PPh3催化下（5/10 mol％）RMgCl（R = Me，Et，n Pr，CH = CH 2，n Bu，i Bu，n C 5 H 11，c C 6 H 11，Bn ，CH 2 Bn，n C 11 H 23）容易地（–78°C）对Cbz或Boc保护的喹啉-4（1 H）-酮进行1,4加成，从而提供2-烷基-2-3,2-二氢喹啉- 4（1 H）-1 （14例，产率54–99％）。非对称版本需要AlEt 3到Boc保护的乙基6取代的4（1 H）-喹诺酮-3-羧酸盐（6-R基团=所有卤素，n / i / t-烷基，CF 3），收率61-91％，ee 30-86％; 任何卤素，Me或CF 3均可提供最高的立体选择性（76–86％ee）。AlMe 3或Al（n C 8 H 17）3的添加在母体中的添加提供≈45和≈75％ee（6-R = H）。配体（S）‐（BINOL）P–N（CHPh
• 4(1H)-quinolone derivatives
  申请人：——

  公开号：US05081121A1

  公开（公告）日：1992-01-14

  Quinolone derivatives having a quinolone structure: ##STR1## where Yo is O or S are disclosed, which are useful as cardiotonic agents. Typical examples of the quinolone derivatives include: 6,7-dimethoxy-4 (1H) quinolone (compound 6) and 5-hydroxy-6-methoxy-4(1H) quinolone (compound 1) as typical compounds of the formulae[I] and [I'], respectively, shown in the specification.

  具有喹诺酮结构的喹诺酮衍生物被披露，其中Yo是O或S，这些衍生物可用作心力衰竭药物。喹诺酮衍生物的典型例子包括：6,7-二甲氧基-4(1H)喹诺酮（化合物6）和5-羟基-6-甲氧基-4(1H)喹诺酮（化合物1），它们分别是规范中显示的公式[I]和[I']的典型化合物。
• N-(4,5-Dihydro-thiazol-2-yl)-3-quinoline-carboxamides having anxiolytic
  申请人：Roussel Uclaf

  公开号：US04450166A1

  公开（公告）日：1984-05-22

  Novel N-(4,5-dihydro-thiazol-2-yl)-4-hydroxy-3-quinoline-carboxamides of the formula ##STR1## wherein R is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms and R.sub.1 is selected from the group consisting of hydrogen, halogen, linear alkyl of 1 to 4 carbon atoms, branched alkyl of 3 to 5 carbon atoms, alkoxy of 1 to 4 carbon atoms, CF.sub.3 --, CF.sub.3 O--, CF.sub.3 S-- and CH.sub.3 S-- in the 6- or 7-position and their non-toxic, pharmaceutically acceptable acid addition salts having a strong anxiolytic activity and a remarkable affinity for benzodiapines receptors and their preparation.

  化合物的名称为N-(4,5-二氢噻唑-2-基)-4-羟基-3-喹啉羧酰胺，化学式为##STR1##其中R从氢和1至4个碳原子的烷基中选择，R.sub.1从氢、卤素、1至4个碳原子的直链烷基、3至5个碳原子的支链烷基、1至4个碳原子的烷氧基、CF.sub.3 --、CF.sub.3 O--、CF.sub.3 S--和CH.sub.3 S--中选择，位于6-或7-位，以及它们的非毒性、药学上可接受的酸盐，具有强烈的抗焦虑活性和显著的苯二氮平受体亲和力，以及它们的制备方法。
• PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER
  申请人：Jinan University

  公开号：EP3339294A1

  公开（公告）日：2018-06-27

  Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.

  本发明提供了一种如式（I）所示的取代喹诺酮衍生物或其药学上可接受的盐和原药分子及其药物组合物，以及其在制备预防和治疗肿瘤药物中的用途。本发明的喹诺酮衍生物、盐、原药分子及其药物组合物可用作蛋白激酶抑制剂，能有效抑制AXL蛋白激酶的活性，能够抑制各种肿瘤细胞的增殖、迁移和侵袭；可用于制备抗肿瘤药物，特别是用于治疗人类和其他哺乳动物的肿瘤等过度增殖性疾病的药物。